Bristol-Myers Squibb Company (BMY) discovers, licenses, manufactures, and markets biopharmaceutical products worldwide. The company provides a wide range of products for hematology, cardiovascular, oncology, fibrotic, immunology, fibrotic, neuroscience, and covid-19 diseases. It sells its products to wholesalers, pharmacies, retailers, hospitals, clinics, distributors, and government agencies.
On October 4, BMY entered into an agreement with Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies. Under the agreement, BMY would receive access to AUTL’s RQR8 safety switch for cell therapy programs on a target-by-target basis for cancer treatment.
